Pharma BD Deal Intelligence
Amgen's China ambitions become clear with the BeiGene deal, committing $2.7 billion for a 20.5% stake and collaboration to advance 20 oncology medicines in the…
Amgen and BeiGene collaborate to advance 20 oncology medicines in China including XGEVA KYPROLIS BLINCYTO and AMG 510 sotorasib with shared development costs.
BeiGene, Ltd. — the BeiGene counterparty to Amgens 2020 strategic collaboration — announced its new name, BeOne Medicines Ltd., and redomiciliation from the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen entered a strategic collaboration with BeiGene to expand its oncology presence in China, investing $2.7B for a 20.5% equity stake with BeiGene commercializing 20 Amgen oncology products in China.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / BeiGene Ltd. (this deal) | 2020 | $2.8B | 68 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
← Browse all deals · How we score deals
More: 2020 deals · Amgen Inc. deals · Oncology deals